Can serum level of prolactine be a predictor of the diagnoses of irritabl bowel syndrome?

Year 2019, Volume: 11 Issue: 1, 27 - 34, 27.06.2019

Müslüm Güneş

Abstract

Background: To determine serum prolactin levels in IBS patients and to investigate the relationship between C-IBS and D-IBS patients and healty control group PRL levels.
Method: In the present study, 100 patients diagnosed with IBS and 100 healthy individuals who visited the hospital for routine check-up were included. IBS was diagnosed based on the Rome III criteria, and patients with IBS-C, patients with IBS-D and healthy controls were classified into groups 1, 2 and 3, respectively. Fasting venous blood samples were collected from all the participants between 08:00–10:00 a.m. to determine their serum PRL levels.
Results: Of the total participants, 28 (14.0%) were excluded, and the remaining 82 (47.7%) healthy controls and 90 (52.3%) patients with IBS were included in the study. Mean serum PRL levels were 10.47 ± 5.15 ng/ml, 14.33±5.10 ng/ml, 7.38±2.36 ng/ml and 12.17 ± 5.36 ng/ml in patients with all IBS, group 1, group 2 and group 3, respectively (p ˂ 0.05). Mean serum PRL level of group 1 was significantly higher than that of group 2 (95% confidence interval [CI]: 4.626–9.267; p ˂ 0.001).
Conclusion: A statistically significant correlation was observed between serum PRL levels and presence of IBS. Thus, serum PRL level can be possibly used as a low-cost and feasible marker for the diagnosis of IBS, despite the low sensitivity and specificity. Furthermore, future studies demonstrating an improvement in the symptoms of IBS with treatments targeting serum PRL levels will be exciting.

Keywords

Irritable bowel syndrome, prolactin

References

• 1. Drossman DA. Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol 1997;9:327–30.
• 2. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555–64
• 3. Thompson WG. Irritable bowel syndrome: a management strategy. Best Pract Res Clin Gastroenterol 1999;13:453–60.
• 4. Kang JY. Systematic review: The influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther 2005.
• 5. Müller-Lissner SA, Bollani S, Brummer RJ, Coremans G, Dapoigny M, Marshall JK, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001.
• 6. Chey WD, Kurlander J, Eswaran S. Irritable Bowel Syndrome. JAMA 2015;313:949.
• 7. Schmulson MW, Chang L. Diagnostic approach to the patient with irritable bowel syndrome. Am J Med 1999;107:20–6.
• 8. Svendsen JH, Munck LK, Andersen JR. Irritable Bowel Syndrome–Prognosis and Diagnostic Safety. Scand J Gastroenterol 1985;20:415–8.
• 9. Liu Q, Wang EM, Yan XJ, Chen SL. Autonomic functioning in irritable bowel syndrome measured by heart rate variability: A meta-analysis. J Dig Dis 2013.
• 10. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. Gastroenterology 2006.
• 11. Thompson WG. Irritable bowel syndrome: Guidlines for the diagnosis. Gastroenterol Int, 1989:92–95.
• 12. Eriksson EM, Andrén KI, Eriksson HT, Kurlberg GK. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers. World J Gastroenterol 2008;14:4889.
• 13. Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidencebased medicine. World J Gastroenterol 2014;20:6759.
• 14. Mearin F, Balboa A, Badía X, Baró E, Caldwell E, Cucala M, et al. Irritable bowel syndrome subtypes according to bowel habit. Eur J Gastroenterol Hepatol 2003;15:165–72.
• 15. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012;11:A465-70.
• 16. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639–69.
• 17. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev 2002;1:360–4.
• 18. Spiller RC. Potential Biomarkers. Gastroenterol Clin North Am 2011;40:121–39.
• 19. Zhang H, Yan Y, Shi R, Lin Z, Wang M, Lin L. Correlation of Gut Hormones with Irritable Bowel Syndrome. Digestion 2008;78:72–6.
• 20. Lawrence CB, Ellacott KLJ, Luckman SM. PRL-releasing peptide reduces food intake and may mediate satiety signaling. Endocrinology 2002.
• 21. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006;130:1377–90.
• 22. Lovell RM, Ford AC. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol 2012.
• 23. Inadomi JM, Fennerty MB, Bjorkman D. The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:671–82.
• 24. Sperber AD, Weisberg I, Skibin A, Neumann L, Fich A, Buskila D. Serum Interleukin1, Interleukin-2, Interleukin 6, and Prolactin Levels Are Not Associated with the Severity of Disease in Patients with the Irritable Bowel Syndrome, with or Without Concomitant Fibromyalgia. J Musculoskelet Pain 1999;7:15–27.
• 25. Heitkemper M, Jarrett M, Cain K, Shaver J, Bond E, Woods NF, et al. Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol 1996.
• 26. Seretis C, Seretis F, Liakos N, Pappas A, Keramidaris D, Gourgiotis S, et al. Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia. Case Rep Gastroenterol 2011;5:523–7.